Lamivudine/Zidovudine Viatris

Lamivudine and Zidovudine, the active ingredients in Lamivudine/Zidovudine Viatris, are nucleoside reverse transcriptase inhibitors presented as oral tablets for oral use. They are employed in the treatment of HIV infection and AIDS in adult and pediatric patients. They are administered as part of combination antiretroviral therapy to achieve durable viral suppression.

GNH USA supplies Lamivudine/Zidovudine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance for global HIV treatment programs.

Lamivudine/Zidovudine is used as a nucleoside reverse transcriptase inhibitor regimen for HIV‑related conditions. - Human immunodeficiency virus (HIV) infection: reduces plasma viral load and delays disease progression. - Acquired immunodeficiency syndrome (AIDS): improves immune function and reduces opportunistic infections. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when given to pregnant women.

Lamivudine/Zidovudine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Anemia

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Neutropenia - Hypersensitivity reactions (including rash and Stevens‑Johnson syndrome)

Before initiating Lamivudine/Zidovudine, clinicians should consider several safety measures to minimise risk. - Baseline and periodic monitoring of complete blood count: detect anemia or neutropenia early. - Assess liver function tests before and during therapy: identify hepatotoxicity. - Evaluate renal function: dose adjustment may be required in impaired clearance. - Avoid use in patients with known hypersensitivity to either component: discontinue if reaction occurs. - Use with caution during pregnancy and breastfeeding: weigh benefits against potential risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudine/Zidovudine can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis and mitochondrial toxicity. - Stavudine: heightened mitochondrial toxicity leading to lactic acidosis. - Alcohol: may exacerbate hepatotoxic effects.

Moderate Interactions (Monitor Closely): - Rifampin: reduces plasma concentrations of both agents, potentially compromising antiviral effect. - Nevirapine: may increase risk of liver enzyme elevations. - Efavirenz: can affect plasma levels of lamivudine, requiring monitoring.